Join Medicilon at the 15th World ADC San Diego 2024

World ADC San Diego 2024

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. 15th World ADC San Diego 2024 is only two weeks to go! We are excited to invite you to visit us at Medicilon Booth #512. Our Science and Business teams are looking forward to meeting you.

Date: November 4-7, 2024

Location: Town & Country San Diego 500 Hotel Circle North

Medicilon ADC R&D Service Platform

In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. To date, Medicilon has spearheaded over 100 significant IND application biopharmaceutical projects, encompassing monoclonal antibodies, bispecific antibodies, polyclonal antibodies, ADCs, viral vaccines, and fusion proteins. As of August 2024, Medicilon has successfully assisted clients on the IND approval of 28 ADC drugs and has multiple ADC projects on going.